An Isolated Intestinal Cannabinoid Study Found Two-Way Cross-Tolerance but Unequal Antagonist Withdrawal Responses

A 1999 isolated guinea-pig intestinal-tissue experiment found bidirectional cross-tolerance between morphine and WIN 55,212-2. Yet antagonist-triggered contraction did not appear symmetrically, limiting a simple claim that the two dependence states were identical.

The model measured tissue responses

Myenteric-plexus longitudinal-muscle preparations were incubated with the compounds and tested through electrically evoked contractions. This was an in-vitro tissue model, not a whole-animal behavior or a human withdrawal assessment.

Cross-tolerance transferred in both directions

Prior exposure to either compound reduced sensitivity to the other's inhibitory effect. WIN exposure also changed the concentration-response curve and maximal inhibition. Those findings characterize local adaptation without identifying every underlying mechanism.

The withdrawal challenges diverged

Naloxone produced a contracture in morphine-tolerant tissue that WIN pretreatment reduced. The cannabinoid antagonist did not produce a significant contracture in WIN-tolerant tissue at a concentration shown to antagonize its effect in controls. Keeping that null result prevents overstating symmetry.

Interpreting the evidence

The authors left the mechanisms unresolved. This experiment supports separating cross-tolerance from the particular withdrawal test used to assess dependence. It does not establish that cannabis treats opioid withdrawal in people or that a tissue contracture predicts clinical symptoms.

Related reading: interpreting cannabis tolerance claims.

Research reference

Basilico L; Parolaro D; Colleoni M; Costa B; Giagnoni G (1999). Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. European journal of pharmacology. doi:10.1016/s0014-2999(99)00389-1.

This analysis draws on the supplied abstract.